Literature DB >> 15827131

RNA interference in biology and disease.

Carol A Sledz1, Bryan R G Williams.   

Abstract

RNA interference (RNAi) is a conserved biologic response to double-stranded RNA that results in the sequence-specific silencing of target gene expression. Over the past 5 years, an intensive research effort has facilitated the rapid movement of RNAi from a relatively obscure biologic phenomenon to a valuable tool used to silence target gene expression and perform large-scale functional genomic screens. In fact, recent studies reported in this journal and others have demonstrated success using RNAi to address the role of oncogene expression in leukemia cell lines and to validate the therapeutic potential of RNAi for treating these blood disorders. In order to advance these applications and gain an appreciation for the future of RNAi both in basic research and in the treatment of diseases caused by aberrant gene expression, it is important to have an understanding of the process of RNAi and its limitations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827131      PMCID: PMC1895153          DOI: 10.1182/blood-2004-12-4643

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  77 in total

1.  Synthetic shRNAs as potent RNAi triggers.

Authors:  Despina Siolas; Cara Lerner; Julja Burchard; Wei Ge; Peter S Linsley; Patrick J Paddison; Gregory J Hannon; Michele A Cleary
Journal:  Nat Biotechnol       Date:  2004-12-26       Impact factor: 54.908

Review 2.  Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.

Authors:  Jessica M Lindvall; K Emelie M Blomberg; Jouni Väliaho; Leonardo Vargas; Juhana E Heinonen; Anna Berglöf; Abdalla J Mohamed; Beston F Nore; Mauno Vihinen; C I Edvard Smith
Journal:  Immunol Rev       Date:  2005-02       Impact factor: 12.988

Review 3.  How cells respond to interferons.

Authors:  G R Stark; I M Kerr; B R Williams; R H Silverman; R D Schreiber
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

4.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

5.  The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1.

Authors:  I Kitabayashi; K Ida; F Morohoshi; A Yokoyama; N Mitsuhashi; K Shimizu; N Nomura; Y Hayashi; M Ohki
Journal:  Mol Cell Biol       Date:  1998-02       Impact factor: 4.272

6.  The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.

Authors:  Ryan T Phan; Riccardo Dalla-Favera
Journal:  Nature       Date:  2004-12-02       Impact factor: 49.962

7.  Monitoring the effect of gene silencing by RNA interference in human CD34+ cells injected into newborn RAG2-/- gammac-/- mice: functional inactivation of p53 in developing T cells.

Authors:  Ramon Gimeno; Kees Weijer; Arie Voordouw; Christel H Uittenbogaart; Nicolas Legrand; Nuno L Alves; Erwin Wijnands; Bianca Blom; Hergen Spits
Journal:  Blood       Date:  2004-08-19       Impact factor: 22.113

8.  RNAi-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells.

Authors:  Raquel Pluvinet; Jordi Pétriz; Joan Torras; Inmaculada Herrero-Fresneda; Josep M Cruzado; Josep M Grinyó; Josep M Aran
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

9.  Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phosphorylation of eukaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus growth.

Authors:  E F Meurs; Y Watanabe; S Kadereit; G N Barber; M G Katze; K Chong; B R Williams; A G Hovanessian
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

10.  The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript.

Authors:  H Miyoshi; T Kozu; K Shimizu; K Enomoto; N Maseki; Y Kaneko; N Kamada; M Ohki
Journal:  EMBO J       Date:  1993-07       Impact factor: 11.598

View more
  35 in total

1.  Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.

Authors:  David E Hurtado; Laura Molina-Porcel; Jenna C Carroll; Caryn Macdonald; Awo K Aboagye; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

2.  Silencing and complementation of reovirus core protein mu2: functional correlations with mu2-microtubule association and differences between virus- and plasmid-derived mu2.

Authors:  John Carvalho; Michelle M Arnold; Max L Nibert
Journal:  Virology       Date:  2007-04-23       Impact factor: 3.616

3.  Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer.

Authors:  Natasa Anastasov; Margit Klier; Ina Koch; Daniela Angermeier; Heinz Höfler; Falko Fend; Leticia Quintanilla-Martinez
Journal:  J Hematop       Date:  2008-11-19       Impact factor: 0.196

4.  Optimization of a Genome-Wide Disordered Lentivector-Based Short Hairpin RNA Library.

Authors:  O A Guryanova; M Makhanov; A A Chenchik; P M Chumakov; E I Frolova
Journal:  Mol Biol       Date:  2006-05-01       Impact factor: 1.374

5.  TGF-β₁-siRNA delivery with nanoparticles inhibits peritoneal fibrosis.

Authors:  H Yoshizawa; Y Morishita; M Watanabe; K Ishibashi; S Muto; E Kusano; D Nagata
Journal:  Gene Ther       Date:  2015-01-08       Impact factor: 5.250

Review 6.  Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

Authors:  Nishant S Gandhi; Rakesh K Tekade; Mahavir B Chougule
Journal:  J Control Release       Date:  2014-09-07       Impact factor: 9.776

7.  Toxicity profiling of several common RNAi-based nanomedicines: a comparative study.

Authors:  Dalit Landesman-Milo; Dan Peer
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

8.  Knockdown of survivin expression by siRNA induces apoptosis of hepatocellular carcinoma cells.

Authors:  Liang Wu; Ying Wang; Deying Tian
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-08

9.  A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.

Authors:  Li Lin; Brian Hutzen; Pui-Kai Li; Sarah Ball; Mingxin Zuo; Stephanie DeAngelis; Elizabeth Foust; Matthew Sobo; Lauren Friedman; Deepak Bhasin; Ling Cen; Chenglong Li; Jiayuh Lin
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

10.  Analysis of Rex1 (zfp42) function in embryonic stem cell differentiation.

Authors:  Kymora B Scotland; Siming Chen; Renia Sylvester; Lorraine J Gudas
Journal:  Dev Dyn       Date:  2009-08       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.